T1	CHEM 14 23	lidocaína
#1	AnnotatorNotes T1	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T2	CHEM 617 619	O2
#2	AnnotatorNotes T2	C0030054; oxygen; Biologically Active Substance · Element, Ion, or Isotope · Pharmacologic Substance
T3	CHEM 64 78	interleucina-6
#3	AnnotatorNotes T3	C0021760; interleukin-6; Amino Acid, Peptide, or Protein · Immunologic Factor | C1698754; IL6 protein, human; Amino Acid, Peptide, or Protein · Biologically Active Substance | C2983957; interleukin-6, human; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	ANAT 79 89	plasmática
#4	AnnotatorNotes T4	C0032105; Plasma; Body Substance
T5	PROC 115 128	histerectomía
#5	AnnotatorNotes T5	C0020699; Hysterectomy; Therapeutic or Preventive Procedure
T6	PROC 161 175	interleucina-6
#6	AnnotatorNotes T6	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T7	PROC 177 181	IL-6
#7	AnnotatorNotes T7	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T8	DISO 217 223	trauma
#8	AnnotatorNotes T8	C3263723; Traumatic injury; Injury or Poisoning | C3714660; Trauma; Injury or Poisoning
T9	CHEM 281 290	lidocaína
#9	AnnotatorNotes T9	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T10	CHEM 620 630	isoflurano
#10	AnnotatorNotes T10	C0022180; isoflurane; Organic Chemical · Pharmacologic Substance
T11	PROC 338 342	IL-6
#11	AnnotatorNotes T11	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T12	PROC 357 370	histerectomía
#12	AnnotatorNotes T12	C0020699; Hysterectomy; Therapeutic or Preventive Procedure
T13	PROC 385 449	estudio fue prospectivo, aleatorizado, comparativo y doble ciego
#13	AnnotatorNotes T13	C1579762; comparative study research; Research Activity + C0033522; Prospective Studies; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity
T14	CHEM 504 513	lidocaína
#14	AnnotatorNotes T14	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T15	PROC 585 594	operación
#15	AnnotatorNotes T15	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T16	PROC 599 608	anestesia
#16	AnnotatorNotes T16	C0002903; Anesthesia procedures; Therapeutic or Preventive Procedure
T17	CHEM 727 737	analgésico
#17	AnnotatorNotes T17	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T18	CHEM 753 760	morfina
#18	AnnotatorNotes T18	C0026549; morphine; Organic Chemical · Pharmacologic Substance
T19	PROC 786 790	IL-6
#19	AnnotatorNotes T19	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T20	PROC 823 832	operación
#20	AnnotatorNotes T20	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T21	PROC 1647 1674	niveles plasmáticos de IL-6
#21	AnnotatorNotes T21	C4700788; interleukin-6 in serum or plasma; Laboratory Procedure
T22	CHEM 1223 1230	morfina
#22	AnnotatorNotes T22	C0026549; morphine; Organic Chemical · Pharmacologic Substance
T23	CHEM 1334 1338	IL-6
#23	AnnotatorNotes T23	C0021760; interleukin-6; Amino Acid, Peptide, or Protein · Immunologic Factor | C1698754; IL6 protein, human; Amino Acid, Peptide, or Protein · Biologically Active Substance | C2983957; interleukin-6, human; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	PROC 64 89	interleucina-6 plasmática
#24	AnnotatorNotes T24	C4700788; interleukin-6 in serum or plasma; Laboratory Procedure
T25	PROC 1417 1421	IL-6
#25	AnnotatorNotes T25	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T26	CHEM 1460 1469	lidocaína
#26	AnnotatorNotes T26	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T27	PROC 1315 1338	concentraciones de IL-6
#27	AnnotatorNotes T27	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T28	CHEM 1549 1558	lidocaína
#28	AnnotatorNotes T28	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T29	ANAT 1655 1666	plasmáticos
#29	AnnotatorNotes T29	C0032105; Plasma; Body Substance
T30	CHEM 1670 1674	IL-6
#30	AnnotatorNotes T30	C0021760; interleukin-6; Amino Acid, Peptide, or Protein · Immunologic Factor | C1698754; IL6 protein, human; Amino Acid, Peptide, or Protein · Biologically Active Substance | C2983957; interleukin-6, human; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	PROC 1700 1723	histerectomía abdominal
#31	AnnotatorNotes T31	C0404077; Abdominal hysterectomy; Therapeutic or Preventive Procedure
T32	DISO 56 61	dolor
#32	AnnotatorNotes T32	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T33	DISO 330 335	dolor
#33	AnnotatorNotes T33	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T34	CHEM 541 556	solución salina
#34	AnnotatorNotes T34	C0445115; Normal saline; Inorganic Chemical · Pharmacologic Substance
T35	DISO 661 666	dolor
#35	AnnotatorNotes T35	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T36	DISO 960 965	dolor
#36	AnnotatorNotes T36	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T37	DISO 1022 1027	dolor
#37	AnnotatorNotes T37	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T38	DISO 1632 1637	dolor
#38	AnnotatorNotes T38	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T39	ANAT 1714 1723	abdominal
#39	AnnotatorNotes T39	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T40	Time 31 46	intraoperatoria
#40	AnnotatorNotes T40	C0021891; Intraoperative Period; Temporal Concept | C0456904; Intraoperative; Temporal Concept
T42	LIVB 93 102	pacientes
#41	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	Route 295 305	vía venosa
#42	AnnotatorNotes T43	C1522726; Intravenous Route of Drug Administration; Functional Concept
T45	LIVB 456 465	pacientes
#43	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	Age 467 485	entre 18 y 60 años
T47	Dose 515 524	2 mg/kg-1
T48	Form 541 549	solución
#44	AnnotatorNotes T48	C1382100; Solution Dosage Form; Biomedical or Dental Material
T49	Dose 557 564	al 0,9%
T51	PHYS 672 681	despertar
#45	AnnotatorNotes T51	C0442696; Waking; Physiologic Function
T52	Duration 684 700	6, 12, 18 y 24 h
T53	Duration 764 781	las primeras 24 h
T54	Duration 850 853	5 h
T55	Duration 872 876	24 h
T60	Duration 1140 1154	76 ± 104,4 min
T61	Duration 1170 1185	26,7 ± 23,3 min
T63	Dose 1256 1270	23,5 ± 12,6 mg
T64	Dose 1278 1292	18,7 ± 11,3 mg
T66	Dose 1560 1569	2 mg/kg-1
T67	Route 1580 1590	vía venosa
#46	AnnotatorNotes T67	C1522726; Intravenous Route of Drug Administration; Functional Concept
T70	LIVB 1678 1687	pacientes
#47	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T41	Route 24 30	venosa
#48	AnnotatorNotes T41	C1522726; Intravenous Route of Drug Administration; Functional Concept
T44	Frequency 525 528	h-1
T50	Frequency 1570 1574	/h-1
T56	Dose 1474 1495	856,5 ± 364,1 ng/ml-1
T57	Dose 1504 1523	30,1 ± 14,2 ng/ml-1
T58	Neg_cue 1591 1593	no
T59	Observation 1601 1637	reducción de la intensidad del dolor
A1	Assertion T59 Negated
#49	AnnotatorNotes T59	C5230944; Sensation of pain reduced; Finding
R1	Negation Arg1:T58 Arg2:T59	
T62	Neg_cue 1188 1190	No
T65	CONC 1196 1206	diferencia
A2	Assertion T65 Negated
#50	AnnotatorNotes T65	C1705241; Delta (difference); Quantitative Concept
R2	Negation Arg1:T62 Arg2:T65	
T68	Neg_cue 1376 1378	No
T69	CONC 1384 1394	diferencia
A3	Assertion T69 Negated
#51	AnnotatorNotes T69	C1705241; Delta (difference); Quantitative Concept
R3	Negation Arg1:T68 Arg2:T69	
T71	CONC 928 938	diferencia
A4	Assertion T71 Negated
#52	AnnotatorNotes T71	C1705241; Delta (difference); Quantitative Concept
T72	Neg_cue 920 922	No
R4	Negation Arg1:T72 Arg2:T71	
R5	Has_Route_or_Mode Arg1:T1 Arg2:T41	
T73	Observation 1 7	Efecto
#53	AnnotatorNotes T73	C1518681; Outcome of Therapy; Finding (?)
R6	Causes Arg1:T1 Arg2:T73	
R7	Overlap Arg1:T1 Arg2:T40	
R9	Location_of Arg1:T4 Arg2:T24	
R10	Experiences Arg1:T42 Arg2:T5	
R11	Experiences Arg1:T42 Arg2:T24	
R12	Experiences Arg1:T42 Arg2:T32	
R13	Experiences Arg1:T42 Arg2:T1	
R14	Experiences Arg1:T42 Arg2:T73	
R15	Causes Arg1:T5 Arg2:T32	
R18	Has_Route_or_Mode Arg1:T9 Arg2:T43	
T74	Observation 268 274	efecto
#54	AnnotatorNotes T74	C1518681; Outcome of Therapy; Finding (?)
R19	Causes Arg1:T9 Arg2:T74	
R20	After Arg1:T11 Arg2:T12	
R21	After Arg1:T74 Arg2:T12	
R22	After Arg1:T9 Arg2:T12	
R23	Causes Arg1:T12 Arg2:T33	
R24	Has_Age Arg1:T45 Arg2:T46	
R25	Has_Dose_or_Strength Arg1:T14 Arg2:T47	
R26	Has_Frequency Arg1:T14 Arg2:T44	
R27	Has_Drug_Form Arg1:T34 Arg2:T48	
R28	Has_Dose_or_Strength Arg1:T34 Arg2:T49	
R29	Overlap Arg1:T14 Arg2:T15	
R30	Overlap Arg1:T34 Arg2:T15	
R33	Used_for Arg1:T2 Arg2:T16	
R35	Combined_with Arg1:T2 Arg2:T10	
R34	After Arg1:T35 Arg2:T51	
R36	Overlap Arg1:T35 Arg2:T52	
R37	Overlap Arg1:T18 Arg2:T53	
R38	Before Arg1:T35 Arg2:T17	
R39	Overlap Arg1:T17 Arg2:T53	
R40	Before Arg1:T19 Arg2:T20	
R41	Overlap Arg1:T19 Arg2:T54	
R42	Overlap Arg1:T19 Arg2:T55	
T75	CONC 858 864	inicio
#55	AnnotatorNotes T75	C0439659; Beginning; Temporal Concept
T76	Observation 989 1027	disminución de la intensidad del dolor
#56	AnnotatorNotes T76	C5230944; Sensation of pain reduced; Finding
R44	Before Arg1:T37 Arg2:T76	
T77	CONC 1081 1119	tiempo para la primera complementación
R45	Has_Duration_or_Interval Arg1:T77 Arg2:T60	
R46	Has_Duration_or_Interval Arg1:T77 Arg2:T61	
T78	Quantifier_or_Qualifier 1231 1245	complementaria
R47	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T78	
R48	Has_Dose_or_Strength Arg1:T22 Arg2:T63	
R49	Has_Dose_or_Strength Arg1:T22 Arg2:T64	
T79	Observation 1300 1338	aumento en las concentraciones de IL-6
#57	AnnotatorNotes T79	C3278574; Increased IL-6; Finding | C4280771; Increased circulating interleukin 6; Finding (?)
T80	CONC 1214 1219	dosis
#58	AnnotatorNotes T80	C0178602; Dosage; Quantitative Concept
T81	CONC 1401 1413	dosificación
#59	AnnotatorNotes T81	C0178602; Dosage; Quantitative Concept
T82	CONC 744 749	dosis
#60	AnnotatorNotes T82	C0178602; Dosage; Quantitative Concept
R50	Overlap Arg1:T82 Arg2:T53	
R51	Has_Dose_or_Strength Arg1:T26 Arg2:T56	
R52	Has_Dose_or_Strength Arg1:T26 Arg2:T57	
R53	Has_Dose_or_Strength Arg1:T28 Arg2:T66	
R54	Has_Frequency Arg1:T28 Arg2:T50	
R55	Has_Route_or_Mode Arg1:T28 Arg2:T67	
R56	Before Arg1:T38 Arg2:T59	
R57	Before Arg1:T28 Arg2:T59	
R58	Location_of Arg1:T29 Arg2:T21	
T83	Observation 1601 1610;1640 1674	reducción de los niveles plasmáticos de IL-6
R59	Experiences Arg1:T70 Arg2:T38	
R60	Experiences Arg1:T70 Arg2:T59	
R61	Experiences Arg1:T70 Arg2:T83	
R62	Experiences Arg1:T70 Arg2:T31	
R63	Location_of Arg1:T39 Arg2:T31	
R65	Causes Arg1:T31 Arg2:T38	
R66	Experiences Arg1:T70 Arg2:T28	
R68	Used_for Arg1:T81 Arg2:T25	
R69	Used_for Arg1:T80 Arg2:T22	
R16	Used_for Arg1:T82 Arg2:T18	
R17	After Arg1:T19 Arg2:T75	
A5	Experiencer T42 Patient
A6	Experiencer T45 Patient
A7	Experiencer T70 Patient
R8	Has_Result_or_Value Arg1:T27 Arg2:T79	
R31	Has_Result_or_Value Arg1:T21 Arg2:T83	
